Loading organizations...
Clinical stage biopharmaceutical company developing innovative medicines.
BioShin has raised $60.0M across 1 funding round.
BioShin has raised $60.0M in total across 1 funding round.
BioShin has raised $60.0M in total across 1 funding round.
BioShin's investors include David Wang, Cormorant Asset Management, HBM Healthcare Investments, Surveyor Capital, Suvretta Capital Management.
BioShin has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series A in September 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 28, 2020 | $60.0M Series A | David Wang | Cormorant Asset Management, HBM Healthcare Investments, Surveyor Capital, Suvretta Capital Management |